The Absorption Study (Geelong)
The study drug is a potential new treatment for PKU (short for phenylketonuria).
This is a rare genetic disease that causes a build-up of phenylalanine, which is a natural amino acid that is found in the human body. Toxic concentrations of this amino acid can lead to intellectual disability in children, behavioural problems, attention deficit disorders, epilepsy, depression, and anxiety. The drug is an oral suspension that is mixed with water.
Patients with PKU currently have very limited treatment options. There are only two medications approved, one of which is not effective for most patients. The other medication requires up to 3 daily injections and has an increased risk of serious allergic reactions. Due to the limited treatment options, it is important that more efficient treatments are developed.
This clinical trial has been approved by an independent ethics committee, and you will be reimbursed for your time.
Call us on 1800 243 733 to discuss your eligibility today!